Revenue ($USD) : $20,498,000,000
R&D spend : $1,388,000,000
Employees : 52,000
Fiscal year end : 12/31/2023
CEO : Kevin Lobo

www.stryker.com

Still riding the success of its Mako robotic orthopedic surgery systems and digital surgery systems, Stryker has gone on offense with M&A. Recent tuck-in acquisitions for the orthopedic and surgical tech giant include Artelon and its soft tissue fixation products for foot and ankle and sports medicine procedures, and Molli Surgical, which develops wire-free soft tissue localization technology for breast-conserving surgery. Stryker Chair and CEO Kevin Lobo recently indicated that the company has a very active deal pipeline for even more M&A. He said a soft-tissue surgical robotics play is a possibility, as well something in the neuromodulation space down the road. Notable updates include the myMako app for Apple Vision Pro, which enhances surgeons' ability to visualize and plan surgeries. Stryker also introduced the Triathlon Hinge within its knee surgery offerings, aiming to simplify revision procedures​. Analysts expect Stryker to enjoy even more growth on shoulder and spine applications for Mako that are slated for later this year. –CN

MORE ON MDO: How 3D printing and surgical robotics enable Stryker’s cementless knee implants